X4 Pharmaceuticals Stock Performance
| XFOR Stock | USD 2.85 0.29 9.24% |
On a scale of 0 to 100, X4 Pharmaceuticals holds a performance score of 3. The firm owns a Beta (Systematic Risk) of 4.0, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, X4 Pharmaceuticals will likely underperform. Please check X4 Pharmaceuticals' potential upside, and the relationship between the jensen alpha and accumulation distribution , to make a quick decision on whether X4 Pharmaceuticals' current price history will revert.
Risk-Adjusted Performance
Soft
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in X4 Pharmaceuticals are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Even with relatively unfluctuating basic indicators, X4 Pharmaceuticals reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (9.24) | Five Day Return 90 | Year To Date Return (87.37) | Ten Year Return (99.89) | All Time Return (99.89) |
Last Split Factor 1:30 | Dividend Date 2019-03-14 | Last Split Date 2025-04-28 |
1 | Insider Trading | 05/20/2025 |
2 | Acquisition by Wyzga Michael S of 1500 shares of X4 Pharmaceuticals subject to Rule 16b-3 | 06/09/2025 |
3 | X4 Pharmaceuticals Gains FDA Fast Track Status for Mavorixafor XFOR Stock News | 06/10/2025 |
4 | X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster ... | 06/16/2025 |
5 | X4 Pharmaceuticals Completes Key Study on Mavorixafors Drug Interaction Potential - TipRanks | 07/01/2025 |
6 | What analysts say about X4 Pharmaceuticals Inc. stock - Market-crushing stock picks - Jammu Links News | 07/18/2025 |
7 | Is X4 Pharmaceuticals Inc. a good long term investment - High-profit trading signals - jammulinksnews.com | 07/22/2025 |
8 | Disposition of 787 shares by Arthur Taveras of X4 Pharmaceuticals at 1.0072 subject to Rule 16b-3 | 07/30/2025 |
9 | X4 Pharmaceuticals Announces 60 Million Equity Financing with Concurrent Changes in Management and Board Leadership | 08/12/2025 |
10 | X4 Pharmaceuticals Announces Closing of Upsized 85 Million Private Placement | 08/13/2025 |
11 | Acquisition by Kirske David of 193254 shares of X4 Pharmaceuticals subject to Rule 16b-3 | 08/14/2025 |
| Begin Period Cash Flow | 100.2 M | |
| Total Cashflows From Investing Activities | 67 M |
X4 Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 292.00 in X4 Pharmaceuticals on May 18, 2025 and sell it today you would lose (7.00) from holding X4 Pharmaceuticals or give up 2.4% of portfolio value over 90 days. X4 Pharmaceuticals is currently generating 0.5939% in daily expected returns and assumes 12.9294% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than XFOR, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
X4 Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for X4 Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as X4 Pharmaceuticals, and traders can use it to determine the average amount a X4 Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0459
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | XFOR | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 12.93 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.59 actual daily | 11 89% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 3 97% of assets perform better |
Based on monthly moving average X4 Pharmaceuticals is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of X4 Pharmaceuticals by adding it to a well-diversified portfolio.
X4 Pharmaceuticals Fundamentals Growth
XFOR Stock prices reflect investors' perceptions of the future prospects and financial health of X4 Pharmaceuticals, and X4 Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on XFOR Stock performance.
| Return On Equity | -2.07 | ||||
| Return On Asset | -0.42 | ||||
| Operating Margin | (13.30) % | ||||
| Current Valuation | 50.9 M | ||||
| Shares Outstanding | 11.41 M | ||||
| Price To Book | 9.02 X | ||||
| Price To Sales | 1.09 X | ||||
| Revenue | 2.56 M | ||||
| Gross Profit | 27.2 M | ||||
| EBITDA | (27.58 M) | ||||
| Net Income | (37.45 M) | ||||
| Cash And Equivalents | 47.38 M | ||||
| Cash Per Share | 0.69 X | ||||
| Total Debt | 78.09 M | ||||
| Debt To Equity | 1.28 % | ||||
| Current Ratio | 2.39 X | ||||
| Book Value Per Share | 0.50 X | ||||
| Cash Flow From Operations | (130.9 M) | ||||
| Earnings Per Share | (15.14) X | ||||
| Market Capitalization | 35.82 M | ||||
| Total Asset | 146.45 M | ||||
| Retained Earnings | (515.36 M) | ||||
| Working Capital | 79.3 M | ||||
About X4 Pharmaceuticals Performance
Assessing X4 Pharmaceuticals' fundamental ratios provides investors with valuable insights into X4 Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the X4 Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1.5 K | 1.3 K | |
| Return On Tangible Assets | (0.31) | (0.33) | |
| Return On Capital Employed | (0.32) | (0.34) | |
| Return On Assets | (0.26) | (0.27) | |
| Return On Equity | (1.69) | (1.78) |
Things to note about X4 Pharmaceuticals performance evaluation
Checking the ongoing alerts about X4 Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for X4 Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| X4 Pharmaceuticals is way too risky over 90 days horizon | |
| X4 Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| X4 Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.56 M. Net Loss for the year was (37.45 M) with profit before overhead, payroll, taxes, and interest of 27.2 M. | |
| X4 Pharmaceuticals currently holds about 47.38 M in cash with (130.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.69. | |
| X4 Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from seekingalpha.com: Acumen expects ALTITUDE-AD Phase II top line results in late 2026 as JCR partnership advances next-generation Alzheimers candidates |
- Analyzing X4 Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether X4 Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining X4 Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating X4 Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of X4 Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of X4 Pharmaceuticals' stock. These opinions can provide insight into X4 Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for XFOR Stock Analysis
When running X4 Pharmaceuticals' price analysis, check to measure X4 Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy X4 Pharmaceuticals is operating at the current time. Most of X4 Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of X4 Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move X4 Pharmaceuticals' price. Additionally, you may evaluate how the addition of X4 Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.